Therapeutic targets for bone metastases in breast cancer

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DISEASE; BONE MARROW; BONE TUMOR; BREAST TUMOR; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; METASTASIS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; REVIEW;

BONE DISEASES; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS;

EID: 80052701557     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2835     Document Type: Review

References (56)

1. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009, 9:285-293. 10.1038/nrc2621, 19308068.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593. 10.1038/nrc867, 12154351.
3. Clézardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007, 24:599-608. 10.1007/s10585-007-9112-8, 18008175.
4. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205. 10.1016/j.ccr.2010.12.022, 21295524.
5. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150. 10.1196/annals.1443.016, 19076348.
6. Leto G. Activin A and bone metastasis. J Cell Physiol 2010, 225:302-309. 10.1002/jcp.22272, 20533297.
7. Clézardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011, 48:71-79. 10.1016/j.bone.2010.07.016, 20655399.
8. Kearns AE, Khosla S, Kostenuik PJ. Receptor of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192. 10.1210/er.2007-0014, 2528846, 18057140.
9. Sabbota AL, Kim HRC, Zhe X, Fridman R, Bonfil RD, Cher ML. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010, 70:5558-5566. 10.1158/0008-5472.CAN-09-4416, 2896434, 20551048.
10. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107. 10.1038/nature09495, 20881963.
11. Stopeck AT, Lipton A, Body JJ, Steger GS, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139. 10.1200/JCO.2010.29.7101, 21060033.
12. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280. 10.1016/S1470-2045(10)70010-3, 20149736.
13. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VLJ, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the avb3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007, 176:877-888. 10.1083/jcb.200611083, 2064061, 17353363.
14. Clézardin P. Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 2009, 9:801-806. 10.2174/156800909789760348, 20025568.
15. Bäuerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2010, 128:2453-2462.
16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22. 10.1038/nrc2748, 20029421.
17. Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005, 90:2022-2028. 10.1210/jc.2004-2126, 15687321.
18. Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. SRC inhibitors in metastatic bone disease. Clin Cancer Res 2006, 12:6291s-6295s. 10.1158/1078-0432.CCR-06-0991, 17062716.
19. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003, 100:14205-14210. 10.1073/pnas.2234372100, 283570, 14612570.
20. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer bone metastasis. Cancer Res 2003, 63:5028-5033.
21. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006, 318:161-172. 10.1124/jpet.106.102004, 16627750.
22. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78. 10.1016/j.ccr.2009.05.017, 2749247, 19573813.
23. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010, 16:4876-4883. 10.1158/1078-0432.CCR-10-0748, 20805299.
24. Kim LC, Song L, Haura EB. SRC kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009, 6:587-595. 10.1038/nrclinonc.2009.129, 19787002.
25. Le Gall C, Bonnelye E, Clézardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008, 2:218-222. 10.1097/SPC.0b013e32830baea9, 18685424.
26. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008, 42:200-211. 10.1016/j.bone.2007.09.044, 17962093.
27. Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007, 67:9894-9902. 10.1158/0008-5472.CAN-06-3940, 17942921.
28. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010, 10:452-458. 10.3816/CBC.2010.n.059, 21147688.
29. Choi Y, Arron JR, Townsend MJ. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:543-548. 10.1038/nrrheum.2009.175, 2797318, 19798028.
30. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847, 14695408.
31. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379. 10.1182/blood-2008-11-191577, 2714212, 19417213.
32. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111. 10.1182/blood-2006-09-047712, 1801040, 17068150.
33. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970. 2360424, 17876334.
34. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008, 123:1034-1042. 10.1002/ijc.23625, 18546262.
35. Kawai M, Mödder UI, Khosla S, Rosen CJ. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 2011, 10:141-156. 10.1038/nrd3299, 21283108.
36. Leto G. Activin A and bone metastasis. J Cell Physiol 2010, 225:302-309. 10.1002/jcp.22272, 20533297.
37. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006, 23:117-122. 10.1007/s10585-006-9010-5, 16841234.
38. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P. Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. J Bone Miner Res 2010, 25:2633-2646. 10.1002/jbmr.142, 20533325.
39. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110-116. 10.1038/nrc990, 12563310.
40. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100:10954-10959. 10.1073/pnas.1830978100, 196909, 12941866.
41. Dréau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis 2006, 23:41-53. 10.1007/s10585-006-9016-z, 16826430.
42. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004, 64:2461-2468. 10.1158/0008-5472.CAN-03-1069, 15059899.
43. Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res 2010, 16:4084-4093. 10.1158/1078-0432.CCR-10-0600, 20643782.
44. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer. , http://www.astrazeneca.com/Media/Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN
45. Juárez P, Guise TA. TGFb pathway as a therapeutic target in bone metastases. Curr Pharm Des 2010, 16:1301-1312. 10.2174/138161210791034049, 20166977.
46. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4:e6896. 10.1371/journal.pone.0006896, 2731927, 19727403.
47. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. Doxorubicin in combination with a small TGFb inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PloS One 2010, 5:e10365. 10.1371/journal.pone.0010365, 2860989, 20442777.
48. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
49. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, van der Pluijm G. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007, 171:1047-1057. 10.2353/ajpath.2007.070168, 1959502, 17724140.
50. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007, 67:8742-8751. 10.1158/0008-5472.CAN-06-2490, 17875715.
51. Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des 2010, 16:1284-1290. 10.2174/138161210791034012, 20166978.
52. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009, 21:761-767.
53. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008, 14:7975-7980. 10.1158/1078-0432.CCR-07-4846, 19088012.
54. Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA 2007, 104:14062-14067. 10.1073/pnas.0705203104, 1955795, 17715292.
55. Servier Medical Art. , http://www.servier.com/Smart/ImageBank.aspx?id_=729
56. ClinicalTrials.gov. , http://www.clinicaltrials.gov/